体部白癬治療薬の世界市場規模調査＆予測：薬剤別、投与経路別、エンドユーザー別、流通チャネル別、地域別分析、2022-2029年

体部白癬は、皮膚の上層部を侵す真菌感染症です。

体のどの部分でも発生または生成される可能性がありますが、特に脚や腕のglabrous skinに最もよく見られます。体部白癬は、白癬菌としても知られ、皮膚に環状構造として現れます。白癬菌は、Trichophyton rubrum、Microsporum canis、Epidermophyton floccosumの3種類で、体部白癬の原因となる真菌です。真菌感染症の発生率の増加や抗真菌薬の需要の高まりは、市場の成長を促す主な要因となっています。

米国疾病管理予防センター（CDC）の推計によると-2019年現在、真菌症により毎年75,000件以上の入院が発生し、約900万件の外来受診が起こっています。また、e-pharmaciesの拡大の高まりと世界のヘルスケア支出の増加は、予測期間中に市場に有利な成長機会をもたらすでしょう。例えば、Statistaによると、2021年の世界のe-pharma市場は10億米ドルと推定されており、2031年には48億米ドルに成長すると予測されています。しかし、体部白癬治療薬の高コストと厳しい医薬品承認プロセスが、2022年から2029年の予測期間を通じて市場成長の妨げとなります。

体部白癬治療薬の世界市場調査において考慮された主要地域は、アジア太平洋地域、北米、欧州、中南米、その他世界の地域です。北米は、皮膚の真菌性疾患の発生率の増加や同地域のヘルスケア支出の増加により、売上高で市場を独占しています。一方、アジア太平洋地域は、老齢人口の増加や市場開拓のための投資増加などの要因により、予測期間中に最も高いCAGRで成長すると予想されます。

本調査の目的は、近年におけるさまざまなセグメントと国の市場規模を明らかにし、今後数年間の市場規模を予測することにあります。本レポートは、調査対象国の産業の質的・量的な側面を取り入れるよう設計されています。

また、市場の将来的な成長を規定する促進要因や課題など、重要な側面に関する詳細情報も提供しています。さらに、主要企業の競合情勢や製品提供の詳細な分析とともに、利害関係者が投資するためのミクロ市場での潜在的な機会も組み込んでいます。.

目次

第1章 エグゼクティブサマリー

• マーケットスナップショット
• 世界・セグメント別市場推定・予測、2019年～2029年
  • 体部白癬治療薬市場、地域別、2019-2029年
  • 体部白癬治療薬市場、薬剤別、2019-2029年
  • 体部白癬治療薬市場、投与経路別、2019-2029年
  • 体部白癬治療薬市場、エンドユーザー別、2019-2029年
  • 体部白癬治療薬市場、流通チャネル別、2019-2029年
• 主な動向
• 調査手法
• 調査の前提条件

第2章 体部白癬治療薬の世界市場の定義と範囲

• 調査目的
• 市場の定義と範囲
  • 調査対象範囲
  • 産業の進化
• 本調査の対象となった年
• 通貨換算レート

第3章 体部白癬治療薬の世界市場力学

• 体部白癬治療薬市場の影響分析（2019-2029年）
  • 市場促進要因
    • 真菌感染症の発生率の増加
    • 抗真菌剤の需要拡大
  • 市場の課題
    • 体部白癬治療薬の高価格化について
    • 厳格な医薬品承認プロセス
  • 市場機会
    • e-pharmaciesの拡大が進む
    • 世界的に拡大するヘルスケア支出

第4章 体部白癬治療薬の世界市場産業分析

• ポーターの5フォースモデル
  • 供給企業の交渉力
  • 買い手の交渉力
  • 新規参入業者の脅威
  • 代替品の脅威
  • 競争企業間の敵対関係
• ポーターの5フォースモデルへの未来的アプローチ（2019-2029年）
• PEST分析
  • 政治的
  • 経済的
  • ソーシャル
  • テクニカル
• 主な投資機会
• 主要成功戦略
• 業界関係者見通し
• アナリストの提言と結論

第5章 リスク評価：COVID-19の影響

• COVID-19が業界に与える全体的な影響についての評価
• COVID-19以前とCOVID-19以後の市場シナリオ

第6章 体部白癬治療薬の世界市場：薬物別

• マーケットスナップショット
• 体部白癬治療薬の世界市場：薬剤別、実績 - ポテンシャル分析
• 体部白癬治療薬の世界市場薬品別推定・予測2019-2029
• 体部白癬治療薬市場、サブセグメント分析
  • 抗真菌剤
  • その他

第7章 体部白癬治療薬の世界市場：投与経路別

• マーケットスナップショット
• 体部白癬治療薬の世界市場：投与経路別、業績-潜在能力分析
• 体部白癬治療薬の世界市場投与経路別推定・予測2019-2029
• 体部白癬治療薬市場、サブセグメント分析
  • 経口
  • 外用
  • 非経口

第8章 体部白癬治療薬の世界市場：エンドユーザー別

• マーケットスナップショット
• 体部白癬治療薬の世界市場：エンドユーザー別、実績 - ポテンシャル分析
• 体部白癬治療薬の世界市場エンドユーザー別推定・予測2019-2029
• 体部白癬治療薬市場、サブセグメント分析
  • 病院
  • ホームケア
  • 専門クリニック

第9章 体部白癬治療薬の世界市場：流通チャネル別

• マーケットスナップショット
• 体部白癬治療薬の世界市場：流通チャネル別、実績 - ポテンシャル分析
• 体部白癬治療薬の世界市場推計・予測（流通チャネル別） 2019-2029
• 体部白癬治療薬市場、サブセグメント分析
  • 病院薬局
  • オンライン薬局
  • 小売薬局

第10章 体部白癬治療薬の世界市場：地域別分析

• 体部白癬治療薬市場、地域別市場スナップショット
• 北米
  • 米国
    • 医薬品別の推定・予測、2019年～2029年
    • 投与経路別の推定・予測、2019年～2029年
    • エンドユーザー別の推定・予測、2019年～2029年
    • 流通チャネル別の推定・予測、2019年～2029年
  • カナダ
• 欧州体部白癬治療薬市場スナップショット
  • 英国
  • ドイツ
  • フランス
  • スペイン
  • イタリア
  • その他欧州
• アジア太平洋地域の体部白癬治療薬市場スナップショット
  • 中国
  • インド
  • 日本
  • オーストラリア
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカの体部白癬治療薬市場スナップショット
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ地域
• 世界のその他の地域

第11章 競合情報

• トップ市場戦略
• 企業プロファイル
  • Novartis AG（Switzerland）
    • 主要な情報
    • 概要
    • 財務（データの入手が可能な場合のみ）
    • 製品概要
    • 最近の動向
  • Endo International Inc（Ireland）
  • Teva Pharmaceutical Industries Ltd（Israel）
  • Glenmark Pharmaceuticals Ltd（India）
  • Cipla Inc（India）
  • Dr Reddy's Laboratories Ltd（India）
  • Abbott（U.S.）
  • F. Hoffmann-La Roche Ltd（Switzerland）
  • Pfizer Inc（U.S.）
  • Zydus Group（India）

第12章 調査プロセス

• 調査プロセス
  • データマイニング
  • 分析
  • 市場推定
  • バリデーション
  • 出版
• 調査の特徴
• 調査の前提条件

LIST OF TABLES

• TABLE 1. Global Tinea Corporis Drugs Market, report scope
• TABLE 2. Global Tinea Corporis Drugs Market estimates & forecasts by Region 2019-2029 (USD Billion)
• TABLE 3. Global Tinea Corporis Drugs Market estimates & forecasts by Drugs 2019-2029 (USD Billion)
• TABLE 4. Global Tinea Corporis Drugs Market estimates & forecasts by Route of Administration 2019-2029 (USD Billion)
• TABLE 5. Global Tinea Corporis Drugs Market estimates & forecasts by End-Users 2019-2029 (USD Billion)
• TABLE 6. Global Tinea Corporis Drugs Market estimates & forecasts by Distribution Channel 2019-2029 (USD Billion)
• TABLE 7. Global Tinea Corporis Drugs Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 8. Global Tinea Corporis Drugs Market by region, estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 9. Global Tinea Corporis Drugs Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 10. Global Tinea Corporis Drugs Market by region, estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 11. Global Tinea Corporis Drugs Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 12. Global Tinea Corporis Drugs Market by region, estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 13. Global Tinea Corporis Drugs Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 14. Global Tinea Corporis Drugs Market by region, estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 15. Global Tinea Corporis Drugs Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 16. Global Tinea Corporis Drugs Market by region, estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 17. U.S. Tinea Corporis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 18. U.S. Tinea Corporis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 19. U.S. Tinea Corporis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 20. Canada Tinea Corporis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 21. Canada Tinea Corporis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 22. Canada Tinea Corporis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 23. UK Tinea Corporis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 24. UK Tinea Corporis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 25. UK Tinea Corporis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 26. Germany Tinea Corporis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 27. Germany Tinea Corporis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 28. Germany Tinea Corporis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 29. France Tinea Corporis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 30. France Tinea Corporis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 31. France Tinea Corporis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 32. Italy Tinea Corporis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 33. Italy Tinea Corporis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 34. Italy Tinea Corporis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 35. Spain Tinea Corporis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 36. Spain Tinea Corporis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 37. Spain Tinea Corporis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 38. RoE Tinea Corporis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 39. RoE Tinea Corporis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 40. RoE Tinea Corporis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 41. China Tinea Corporis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 42. China Tinea Corporis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 43. China Tinea Corporis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 44. India Tinea Corporis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 45. India Tinea Corporis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 46. India Tinea Corporis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 47. Japan Tinea Corporis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 48. Japan Tinea Corporis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 49. Japan Tinea Corporis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 50. South Korea Tinea Corporis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 51. South Korea Tinea Corporis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 52. South Korea Tinea Corporis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 53. Australia Tinea Corporis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 54. Australia Tinea Corporis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 55. Australia Tinea Corporis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 56. RoAPAC Tinea Corporis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 57. RoAPAC Tinea Corporis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 58. RoAPAC Tinea Corporis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 59. Brazil Tinea Corporis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 60. Brazil Tinea Corporis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 61. Brazil Tinea Corporis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 62. Mexico Tinea Corporis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 63. Mexico Tinea Corporis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 64. Mexico Tinea Corporis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 65. RoLA Tinea Corporis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 66. RoLA Tinea Corporis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 67. RoLA Tinea Corporis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 68. Row Tinea Corporis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 69. Row Tinea Corporis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 70. Row Tinea Corporis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 71. List of secondary sources, used in the study of global Tinea Corporis Drugs Market
• TABLE 72. List of primary sources, used in the study of global Tinea Corporis Drugs Market
• TABLE 73. Years considered for the study
• TABLE 74. Exchange rates considered

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

List of figures

• FIG 1. Global Tinea Corporis Drugs Market, research methodology
• FIG 2. Global Tinea Corporis Drugs Market, Market estimation techniques
• FIG 3. Global Market size estimates & forecast methods
• FIG 4. Global Tinea Corporis Drugs Market, key trends 2021
• FIG 5. Global Tinea Corporis Drugs Market, growth prospects 2022-2029
• FIG 6. Global Tinea Corporis Drugs Market, porters 5 force model
• FIG 7. Global Tinea Corporis Drugs Market, pest analysis
• FIG 8. Global Tinea Corporis Drugs Market, value chain analysis
• FIG 9. Global Tinea Corporis Drugs Market by segment, 2019 & 2029 (USD Billion)
• FIG 10. Global Tinea Corporis Drugs Market by segment, 2019 & 2029 (USD Billion)
• FIG 11. Global Tinea Corporis Drugs Market by segment, 2019 & 2029 (USD Billion)
• FIG 12. Global Tinea Corporis Drugs Market by segment, 2019 & 2029 (USD Billion)
• FIG 13. Global Tinea Corporis Drugs Market by segment, 2019 & 2029 (USD Billion)
• FIG 14. Global Tinea Corporis Drugs Market, regional snapshot 2019 & 2029
• FIG 15. North America Tinea Corporis Drugs Market 2019 & 2029 (USD Billion)
• FIG 16. Europe Tinea Corporis Drugs Market 2019 & 2029 (USD Billion)
• FIG 17. Asia Pacific Tinea Corporis Drugs Market 2019 & 2029 (USD Billion)
• FIG 18. Latin America Tinea Corporis Drugs Market 2019 & 2029 (USD Billion)
• FIG 19. Global Tinea Corporis Drugs Market, company Market share analysis (2021)

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

Global Tinea Corporis Drugs Market is valued at approximately USD XX billion in 2021 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2022-2029. Tinea corporis is a fungal infection that affects the upper layer of the skin. It can occur or be produced in any part of the body, but it is most commonly found on the legs and arms, particularly in the glabrous skin. Tinea corporis, also known as ringworm, appears on the skin as a ring structure. Trichophyton rubrum, Microsporum canis, and Epidermophyton floccosum are the fungi that cause tinea corporis. The increasing incidence of fungal infections and rising demand for antifungal drugs are key factors driving the market growth.

As per Centers for Disease Control & Prevention (CDC) estimates - as of 2019, fungal diseases resulted in more than 75,000 hospitalizations and around 9 million outpatient visits occur every year for fungal diseases. Also, rising expansion of e-pharmacies and growing healthcare spending worldwide would create lucrative growth opportunities for the market over the projected period. For instance - as per Statista - In 2021, the global e-pharma market was estimated at USD 1 billion, and it is projected to grow to USD 4.8 billion by the year 2031. However, high cost of Tinea Corporis Drugs and stringent drug approval process hinder the market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Tinea Corporis Drugs Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America dominated the market in terms of revenue, owing to the increasing incidence of fungal diseases of skin as well as rising healthcare spending in the region. Whereas Asia Pacific is expected to grow with the highest CAGR during the forecast period, owing to factors such as rising geriatric and target populations, and increasing investment towards new product development from leading market players in the region.

Major market players included in this report are:

• Novartis AG (Switzerland)
• Endo International Inc (Ireland)
• Teva Pharmaceutical Industries Ltd (Israel)
• Glenmark Pharmaceuticals Ltd (India)
• Cipla Inc (India)
• Dr Reddy's Laboratories Ltd (India)
• Abbott (U.S.)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Pfizer Inc (U.S.)
• Zydus Group (India)

Recent Developments in the Market:

• On May 16, 2022 - Shionogi & Co., Ltd. and F2G Ltd. Entered into a strategic collaboration to develop and commercialize the new antifungal agent olorofim for invasive fungal infections in European and Asian markets. This new agent Olorofim is a novel oral antifungal therapy developed by F2G to treat invasive aspergillosis (IA) and other rare mold infections.

Global Tinea Corporis Drugs Market Report Scope:

• Historical Data: 2019-2020-2021
• Base Year for Estimation: 2021
• Forecast period: 2022-2029
• Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
• Segments Covered: Drugs, Route of Administration, End-Users, Distribution Channel, Region
• Regional Scope: North America; Europe; Asia Pacific; Latin America; Rest of the World
• Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below.

By Drugs

• Anti-Fungal
• Others

By Route of Administration

• Oral
• Topical
• Parenteral

By End-Users

• Hospitals
• Homecare
• Specialty Clinics

By Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
• Latin America
• Brazil
• Mexico
• RoLA
• Rest of the World

Table of Contents

Chapter 1. Executive Summary

• 1.1. Market Snapshot
• 1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
  • 1.2.1. Tinea Corporis Drugs Market, by Region, 2019-2029 (USD Billion)
  • 1.2.2. Tinea Corporis Drugs Market, by Drugs, 2019-2029 (USD Billion)
  • 1.2.3. Tinea Corporis Drugs Market, by Route of Administration, 2019-2029 (USD Billion)
  • 1.2.4. Tinea Corporis Drugs Market, by End-Users, 2019-2029 (USD Billion)
  • 1.2.5. Tinea Corporis Drugs Market, by Distribution Channel, 2019-2029 (USD Billion)
• 1.3. Key Trends
• 1.4. Estimation Methodology
• 1.5. Research Assumption

Chapter 2. Global Tinea Corporis Drugs Market Definition and Scope

• 2.1. Objective of the Study
• 2.2. Market Definition & Scope
  • 2.2.1. Scope of the Study
  • 2.2.2. Industry Evolution
• 2.3. Years Considered for the Study
• 2.4. Currency Conversion Rates

Chapter 3. Global Tinea Corporis Drugs Market Dynamics

• 3.1. Tinea Corporis Drugs Market Impact Analysis (2019-2029)
  • 3.1.1. Market Drivers
    • 3.1.1.1. Increasing incidence of fungal infections
    • 3.1.1.2. Growing demand for antifungal drugs
  • 3.1.2. Market Challenges
    • 3.1.2.1. High Cost of Tinea Corporis Drugs
    • 3.1.2.2. Stringent drug approval process
  • 3.1.3. Market Opportunities
    • 3.1.3.1. Rising expansion of e-pharmacies
    • 3.1.3.2. Growing healthcare spending worldwide

Chapter 4. Global Tinea Corporis Drugs Market Industry Analysis

• 4.1. Porter's 5 Force Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
• 4.2. Futuristic Approach to Porter's 5 Force Model (2019-2029)
• 4.3. PEST Analysis
  • 4.3.1. Political
  • 4.3.2. Economical
  • 4.3.3. Social
  • 4.3.4. Technological
• 4.4. Top investment opportunity
• 4.5. Top winning strategies
• 4.6. Industry Experts Prospective
• 4.7. Analyst Recommendation & Conclusion

Chapter 5. Risk Assessment: COVID-19 Impact

• 5.1. Assessment of the overall impact of COVID-19 on the industry
• 5.2. Pre COVID-19 and post COVID-19 Market scenario

Chapter 6. Global Tinea Corporis Drugs Market, by Drugs

• 6.1. Market Snapshot
• 6.2. Global Tinea Corporis Drugs Market by Drugs, Performance - Potential Analysis
• 6.3. Global Tinea Corporis Drugs Market Estimates & Forecasts by Drugs 2019-2029 (USD Billion)
• 6.4. Tinea Corporis Drugs Market, Sub Segment Analysis
  • 6.4.1. Antifungal
  • 6.4.2. Others

Chapter 7. Global Tinea Corporis Drugs Market, by Route of Administration

• 7.1. Market Snapshot
• 7.2. Global Tinea Corporis Drugs Market by Route of Administration, Performance - Potential Analysis
• 7.3. Global Tinea Corporis Drugs Market Estimates & Forecasts by Route of Administration 2019-2029 (USD Billion)
• 7.4. Tinea Corporis Drugs Market, Sub Segment Analysis
  • 7.4.1. Oral
  • 7.4.2. Topical
  • 7.4.3. Parenteral

Chapter 8. Global Tinea Corporis Drugs Market, by End-Users

• 8.1. Market Snapshot
• 8.2. Global Tinea Corporis Drugs Market by End-Users, Performance - Potential Analysis
• 8.3. Global Tinea Corporis Drugs Market Estimates & Forecasts by End-Users 2019-2029 (USD Billion)
• 8.4. Tinea Corporis Drugs Market, Sub Segment Analysis
  • 8.4.1. Hospitals
  • 8.4.2. Homecare
  • 8.4.3. Specialty Clinics

Chapter 9. Global Tinea Corporis Drugs Market, by Distribution Channel

• 9.1. Market Snapshot
• 9.2. Global Tinea Corporis Drugs Market by Distribution Channel, Performance - Potential Analysis
• 9.3. Global Tinea Corporis Drugs Market Estimates & Forecasts by Distribution Channel 2019-2029 (USD Billion)
• 9.4. Tinea Corporis Drugs Market, Sub Segment Analysis
  • 9.4.1. Hospital Pharmacy
  • 9.4.2. Online Pharmacy
  • 9.4.3. Retail Pharmacy

Chapter 10. Global Tinea Corporis Drugs Market, Regional Analysis

• 10.1. Tinea Corporis Drugs Market, Regional Market Snapshot
• 10.2. North America Tinea Corporis Drugs Market
  • 10.2.1. U.S. Tinea Corporis Drugs Market
    • 10.2.1.1. Drugs breakdown estimates & forecasts, 2019-2029
    • 10.2.1.2. Route of Administration breakdown estimates & forecasts, 2019-2029
    • 10.2.1.3. End-Users breakdown estimates & forecasts, 2019-2029
    • 10.2.1.4. Distribution Channel breakdown estimates & forecasts, 2019-2029
  • 10.2.2. Canada Tinea Corporis Drugs Market
• 10.3. Europe Tinea Corporis Drugs Market Snapshot
  • 10.3.1. U.K. Tinea Corporis Drugs Market
  • 10.3.2. Germany Tinea Corporis Drugs Market
  • 10.3.3. France Tinea Corporis Drugs Market
  • 10.3.4. Spain Tinea Corporis Drugs Market
  • 10.3.5. Italy Tinea Corporis Drugs Market
  • 10.3.6. Rest of Europe Tinea Corporis Drugs Market
• 10.4. Asia-Pacific Tinea Corporis Drugs Market Snapshot
  • 10.4.1. China Tinea Corporis Drugs Market
  • 10.4.2. India Tinea Corporis Drugs Market
  • 10.4.3. Japan Tinea Corporis Drugs Market
  • 10.4.4. Australia Tinea Corporis Drugs Market
  • 10.4.5. South Korea Tinea Corporis Drugs Market
  • 10.4.6. Rest of Asia Pacific Tinea Corporis Drugs Market
• 10.5. Latin America Tinea Corporis Drugs Market Snapshot
  • 10.5.1. Brazil Tinea Corporis Drugs Market
  • 10.5.2. Mexico Tinea Corporis Drugs Market
  • 10.5.3. Rest of Latin America Tinea Corporis Drugs Market
• 10.6. Rest of The World Tinea Corporis Drugs Market

Chapter 11. Competitive Intelligence

• 11.1. Top Market Strategies
• 11.2. Company Profiles
  • 11.2.1. Novartis AG (Switzerland)
    • 11.2.1.1. Key Information
    • 11.2.1.2. Overview
    • 11.2.1.3. Financial (Subject to Data Availability)
    • 11.2.1.4. Product Summary
    • 11.2.1.5. Recent Developments
  • 11.2.2. Endo International Inc (Ireland)
  • 11.2.3. Teva Pharmaceutical Industries Ltd (Israel)
  • 11.2.4. Glenmark Pharmaceuticals Ltd (India)
  • 11.2.5. Cipla Inc (India)
  • 11.2.6. Dr Reddy's Laboratories Ltd (India)
  • 11.2.7. Abbott (U.S.)
  • 11.2.8. F. Hoffmann-La Roche Ltd (Switzerland)
  • 11.2.9. Pfizer Inc (U.S.)
  • 11.2.10. Zydus Group (India)

Chapter 12. Research Process

• 12.1. Research Process
  • 12.1.1. Data Mining
  • 12.1.2. Analysis
  • 12.1.3. Market Estimation
  • 12.1.4. Validation
  • 12.1.5. Publishing
• 12.2. Research Attributes
• 12.3. Research Assumption